Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: May, 2016 | Pages:
70 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Transmembrane Prolyl 4-Hydroxylase (Hypoxia-Inducible Factor Prolyl Hydroxylase 4 or EC 1.14.11.) - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Transmembrane Prolyl 4-Hydroxylase (Hypoxia-Inducible Factor Prolyl Hydroxylase 4 or EC 1.14.11.) - Pipeline Review, H1 2016', provides in depth analysis on Transmembrane Prolyl 4-Hydroxylase (Hypoxia-Inducible Factor Prolyl Hydroxylase 4 or EC 1.14.11.) targeted pipeline therapeutics. The report provides comprehensive information on the Transmembrane Prolyl 4-Hydroxylase (Hypoxia-Inducible Factor Prolyl Hydroxylase 4 or EC 1.14.11.), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Transmembrane Prolyl 4-Hydroxylase (Hypoxia-Inducible Factor Prolyl Hydroxylase 4 or EC 1.14.11.) targeted therapeutics development and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape for Transmembrane Prolyl 4-Hydroxylase (Hypoxia-Inducible Factor Prolyl Hydroxylase 4 or EC 1.14.11.) - The report reviews Transmembrane Prolyl 4-Hydroxylase (Hypoxia-Inducible Factor Prolyl Hydroxylase 4 or EC 1.14.11.) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Transmembrane Prolyl 4-Hydroxylase (Hypoxia-Inducible Factor Prolyl Hydroxylase 4 or EC 1.14.11.) targeted therapeutics and enlists all their major and minor projects - The report assesses Transmembrane Prolyl 4-Hydroxylase (Hypoxia-Inducible Factor Prolyl Hydroxylase 4 or EC 1.14.11.) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Transmembrane Prolyl 4-Hydroxylase (Hypoxia-Inducible Factor Prolyl Hydroxylase 4 or EC 1.14.11.) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Transmembrane Prolyl 4-Hydroxylase (Hypoxia-Inducible Factor Prolyl Hydroxylase 4 or EC 1.14.11.) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Transmembrane Prolyl 4-Hydroxylase (Hypoxia-Inducible Factor Prolyl Hydroxylase 4 or EC 1.14.11.) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Transmembrane Prolyl 4-Hydroxylase (Hypoxia-Inducible Factor Prolyl Hydroxylase 4 or EC 1.14.11.) Overview 7 Therapeutics Development 8 Transmembrane Prolyl 4-Hydroxylase (Hypoxia-Inducible Factor Prolyl Hydroxylase 4 or EC 1.14.11.) - Products under Development by Stage of Development 8 Transmembrane Prolyl 4-Hydroxylase (Hypoxia-Inducible Factor Prolyl Hydroxylase 4 or EC 1.14.11.) - Products under Development by Therapy Area 9 Transmembrane Prolyl 4-Hydroxylase (Hypoxia-Inducible Factor Prolyl Hydroxylase 4 or EC 1.14.11.) - Products under Development by Indication 10 Transmembrane Prolyl 4-Hydroxylase (Hypoxia-Inducible Factor Prolyl Hydroxylase 4 or EC 1.14.11.) - Pipeline Products Glance 11 Late Stage Products 11 Early Stage Products 12 Transmembrane Prolyl 4-Hydroxylase (Hypoxia-Inducible Factor Prolyl Hydroxylase 4 or EC 1.14.11.) - Products under Development by Companies 13 Transmembrane Prolyl 4-Hydroxylase (Hypoxia-Inducible Factor Prolyl Hydroxylase 4 or EC 1.14.11.) - Therapeutics Assessment 16 Assessment by Monotherapy/Combination Products 16 Assessment by Mechanism of Action 17 Assessment by Route of Administration 18 Assessment by Molecule Type 20 Transmembrane Prolyl 4-Hydroxylase (Hypoxia-Inducible Factor Prolyl Hydroxylase 4 or EC 1.14.11.) - Companies Involved in Therapeutics Development 21 Akebia Therapeutics, Inc. 21 Bayer AG 22 Daiichi Sankyo Company, Limited 23 FibroGen, Inc. 24 GlaxoSmithKline Plc 25 Japan Tobacco Inc. 26 Merck & Co., Inc. 27 Sigmoid Pharma Limited 28 Transmembrane Prolyl 4-Hydroxylase (Hypoxia-Inducible Factor Prolyl Hydroxylase 4 or EC 1.14.11.) - Drug Profiles 29 AKB-6899 - Drug Profile 29 Product Description 29 Mechanism Of Action 29 R&D Progress 29 daprodustat - Drug Profile 30 Product Description 30 Mechanism Of Action 30 R&D Progress 30 dimethyloxalylglycine - Drug Profile 32 Product Description 32 Mechanism Of Action 32 R&D Progress 32 DS-1093 - Drug Profile 33 Product Description 33 Mechanism Of Action 33 R&D Progress 33 FG-2216 - Drug Profile 34 Product Description 34 Mechanism Of Action 34 R&D Progress 34 FG-4497 - Drug Profile 35 Product Description 35 Mechanism Of Action 35 R&D Progress 35 FG-6874 - Drug Profile 36 Product Description 36 Mechanism Of Action 36 R&D Progress 36 FG-8205 - Drug Profile 37 Product Description 37 Mechanism Of Action 37 R&D Progress 37 JTZ-951 - Drug Profile 38 Product Description 38 Mechanism Of Action 38 R&D Progress 38 molidustat - Drug Profile 39 Product Description 39 Mechanism Of Action 39 R&D Progress 39 roxadustat - Drug Profile 41 Product Description 41 Mechanism Of Action 41 R&D Progress 41 Small Molecules to Inhibit Prolyl Hydroxylase for Anemia - Drug Profile 47 Product Description 47 Mechanism Of Action 47 R&D Progress 47 vadadustat - Drug Profile 48 Product Description 48 Mechanism Of Action 48 R&D Progress 48 Transmembrane Prolyl 4-Hydroxylase (Hypoxia-Inducible Factor Prolyl Hydroxylase 4 or EC 1.14.11.) - Dormant Projects 54 Transmembrane Prolyl 4-Hydroxylase (Hypoxia-Inducible Factor Prolyl Hydroxylase 4 or EC 1.14.11.) - Featured News & Press Releases 55 May 05, 2016: Akebia Provides Update On Phase 3 INNO2VATE Program For Vadadustat 55 Apr 26, 2016: Akebia Therapeutics Announces Presentation of Vadadustat Phase 2 Dialysis Data at Upcoming National Kidney Foundation 2016 Spring Clinical Meetings 56 Apr 20, 2016: Promising Phase 2 Data Show Roxadustat Corrected Anemia In Chronic Kidney Disease Patients Before Intervention With Dialysis 56 Mar 09, 2016: Akebia Prevails in European Patent Dispute and Preserves Access to Key Market for Vadadustat 57 Feb 16, 2016: FibroGen Publishes Encouraging Phase 2 Anemia Data Demonstrating Roxadustat's Ability to Maintain Hemoglobin Levels in Patients With Chronic Kidney Disease 58 Jan 04, 2016: Akebia Initiates Phase 3 PRO2TECT Program 59 Nov 07, 2015: Akebia Announces Presentation of Vadadustat Phase 2 Dialysis Data at American Society of Nephrology Kidney Week 2015 Annual Meeting 60 Nov 03, 2015: FibroGen to Present Roxadustat Clinical Data in Four Presentations at American Society of Nephrology - Kidney Week 2015 61 Oct 28, 2015: Akebia Announces Presentations at the Upcoming American Society of Nephrology Kidney Week 2015 Annual Meeting 61 Oct 22, 2015: Phase 2 Data For Investigational Orally Active Hif-Phi Roxadustat Show Anemia Correction In Incident Dialysis Chronic Kidney Disease Patients Regardless Of Iron Repletion Status, Iron Supplementation Regimen, Or Dialysis Modality 63 Oct 06, 2015: Akebia Reaches Agreement with FDA and EMA on Vadadustat Global Phase 3 Program 64 Sep 08, 2015: Akebia Announces Positive Top-Line Results from its Phase 2 Study of Vadadustat in Dialysis Patients with Anemia Related to Chronic Kidney Disease 65 Aug 12, 2015: Nephrology Dialysis Transplantation Reports Phase 2 Data Of Investigational Orally Active Hif-Phi Roxadustat (Fg-4592) Shows Improved Hemoglobin Levels In Non-Dialysis Ckd Subjects With Anemia 66 May 29, 2015: Akebia Announces Presentation of Phase 2b Data for AKB-6548 in Non-Dialysis Patients with Anemia Related to Chronic Kidney Disease at the 52nd ERA-EDTA Congress 67 May 26, 2015: Akebia Therapeutics Announces Presentation of AKB-6548 Phase 2b Data at the 52nd ERA-EDTA Annual Congress 67 Appendix 69 Methodology 69 Coverage 69 Secondary Research 69 Primary Research 69 Expert Panel Validation 69 Contact Us 69 Disclaimer 70
List of Tables
Number of Products under Development for, H1 2016 8 Number of Products under Development by Therapy Area, H1 2016 9 Number of Products under Development by Indication, H1 2016 10 Comparative Analysis by Late Stage Development, H1 2016 11 Comparative Analysis by Early Stage Products, H1 2016 12 Number of Products under Development by Companies, H1 2016 13 Products under Development by Companies, H1 2016 14 Products under Development by Companies, H1 2016 (Contd..1) 15 Assessment by Monotherapy/Combination Products, H1 2016 16 Number of Products by Stage and Mechanism of Action, H1 2016 17 Number of Products by Stage and Route of Administration, H1 2016 19 Number of Products by Stage and Molecule Type, H1 2016 20 Pipeline by Akebia Therapeutics, Inc., H1 2016 21 Pipeline by Bayer AG, H1 2016 22 Pipeline by Daiichi Sankyo Company, Limited, H1 2016 23 Pipeline by FibroGen, Inc., H1 2016 24 Pipeline by GlaxoSmithKline Plc, H1 2016 25 Pipeline by Japan Tobacco Inc., H1 2016 26 Pipeline by Merck & Co., Inc., H1 2016 27 Pipeline by Sigmoid Pharma Limited, H1 2016 28 Dormant Projects, H1 2016 54
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
